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Abstract: Gliclazide (G) is an antidiabetic drug commonly used in type 2 diabetes. It has 
extrapancreatic hypoglycemic effects, which makes it a good candidate in type 1 diabetes (T1D). 
In previous studies, we have shown that a gliclazide-bile acid mixture exerted a hypoglycemic 
effect in a rat model of T1D. We have also shown that a gliclazide-deoxycholic acid (G-DCA) 
mixture resulted in better G permeation in vivo, but did not produce a hypoglycemic effect. In 
this study, we aimed to develop a novel microencapsulated formulation of G-DCA with uni-
form structure, which has the potential to enhance G pharmacokinetic and pharmacodynamic 
effects in our rat model of T1D. We also aimed to examine the effect that DCA will have when 
formulated with our new G microcapsules, in terms of morphology, structure, and excipients’ 
compatibility. Microencapsulation was carried out using the Büchi-based microencapsulating 
system developed in our laboratory. Using sodium alginate (SA) polymer, both formulations 
were prepared: G-SA (control) at a ratio of 1:30, and G-DCA-SA (test) at a ratio of 1:3:30. 
Complete characterization of microcapsules was carried out. The new G-DCA-SA formulation 
was further optimized by the addition of DCA, exhibiting pseudoplastic-thixotropic rheologi-
cal characteristics. The size of microcapsules remained similar after DCA addition, and these 
microcapsules showed no chemical interactions between the excipients. This was supported 
further by the spectral and microscopy studies, suggesting microcapsule stability. The new 
microencapsulated formulation has good structural properties and may be useful for the oral 
delivery of G in T1D.
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Introduction
Diabetes mellitus is a metabolic disorder classified as type 1 diabetes (T1D) or type 2 
diabetes (T2D). T1D is an early-onset autoimmune disease marked by the destruction 
of β-cells of the pancreas, resulting in a partial or complete lack of insulin production 
and the inability of the body to control glucose homeostasis.1 T2D is a metabolic 
disorder with later onset and is most common in the overweight population.2 T2D is 
caused by genetic and environmental factors, with recent studies showing that loss of 
function gene variants in GPR120 have a strong association with increased risk of T2D 
complications.3,4 Gliclazide (G) is an antidiabetic drug used in T2D to enhance insulin 
secretion, and has beneficial extrapancreatic effects that render it potentially useful 
in T1D.5 In general, controlled absorption of G from the gut is required in order to 
prevent sharp fluctuations in the blood glucose levels after food intake. About 30% of 
a G dose undergoes enterohepatic recirculation, which may contribute to the observed 
high bioavailability, but also high interindividual variability in its absorption after an 





oral dose.6 Thus, bile acids (BAs) may play an important role 
in enhancing G ileal absorption and optimize its efficacy and 
safety profiles.
BAs are known to act as permeation enhancers for 
antidiabetic drugs through the ileal mucosa and through the 
blood–brain barrier.7,8 BAs have also shown potential health 
benefits in diabetes treatment through their endocrinological, 
metabolic, energy expenditure, and other known and 
unknown effects.9,10 Combining BAs with G is anticipated 
to optimize G’s antidiabetic effect. Our studies have shown 
the significant antidiabetic effects of the combination in a rat 
model of T1D.8,11 One of the potential applications of BAs 
on G is through enhancing its permeation. A recent study in 
our laboratory has demonstrated that the BA, deoxycholic 
acid (DCA), enhanced G permeation through the blood–brain 
barrier in T1D rats.8 In order to design this microencapsulated 
formulation of gliclazide-deoxycholic acid-sodium alginate 
(G-DCA-SA), a suitable polymer is needed.
Commonly used polymers in drug microencapsulation 
technology include sodium alignate (SA), chitosan, and 
pectin.12 They are biocompatible and present no signs of 
clinical toxicity.12 SA is the salt of alginic acid, a natural 
polysaccharide derived from seaweed, and consisting of 
variable percentages of (1–4)-linked β-d-mannuronic acid 
and α-l-guluronic acid residues.13 In order to design a novel 
microencapsulated formulation that targets the lower intes-
tine, low-viscosity SA (LVSA) is a good choice.14,15
This study aimed to design a novel G-DCA-SA micro-
encapsulated formulation, using LVSA, that is uniform, bio-
compatible, and thermally stable and which has the potential 
for optimized G delivery.
Materials and methods
Materials
G (99.92%), LVSA (99%), and DCA (99%) were purchased 





O] 98%) was obtained from 
Scharlab SL (Barcelona, Spain). All solvents and reagents 
were supplied by Merck (Darmstadt, Germany), and were of 
high-performance liquid chromatography (HPLC) grade and 
used without further purification.
Drug preparation
Stock suspensions of G (20 mg/mL) and DCA (1 mg/mL) 
were prepared by adding the powder to 10% Ultra-soluble 
gel of 100 mL HPLC water. The CaCl
2
 stock solution (2%) 
was prepared by adding CaCl
2
 powder to HPLC water. All 
preparations were mixed thoroughly at room temperature for 
4 hours, stored in the refrigerator, and used within 48 hours 
of preparation.
Preparation of microcapsules
Microcapsules of G-loaded LVSA were prepared using a Büchi-
based microencapsulating system that operates through jet-flow 
microencapsulation. Parameters were set in a frequency range 
of 1,000–1,500 Hz and a constant flow rate of 4 mL/min. Poly-
mer solutions containing SA and G with or without DCA were 
made up to a final concentration (of G-DCA-SA) in a ratio of 
1:3:30, respectively.16,17 This ratio was based on our previously 
published work and was found to exhibit maximum consistency 
and best morphology.18 Two formulations were prepared, one 
with G (1 mg/mL) in SA solution (30 mg/mL) and the other 
with G (1 mg/mL), and DCA (3 mg/mL). Microcapsules 
were collected from our microencapsulating system and, for 
each formulation, three independent batches were prepared 
and tested separately (n=3). All microcapsules (G-loaded 
and G-DCA-SA-loaded microcapsules) were prepared and 
treated in the exact same way. Microencapsulation efficiency 
was calculated as a percentage based on the total amount of G 
recovered, divided by total G used.
characterization of loaded microcapsules
Morphology, size analysis, and chemical 
characterization of microcapsules
All microcapsules were freshly made, stored in the refrigera-
tor, and used within 48 hours of preparation. The appearance 
and size of microcapsules were examined using light micros-
copy followed by scanning electron microscopy (SEM) and 
energy dispersive X-ray (EDXR) spectrometry. The particle 
size distribution and mean particle size diameter were cal-
culated using SmartSEM V05.03NV software (Carl Zeiss 
AG, Jena, Germany).
seM and eDXr spectroscopy
The surface morphology of the microcapsules was examined 
using SEM (Zeiss Neon 40EsB FIBSEM; Carl Zeiss AG) with 
0.8 nm calibrated resolution. The chemical characterization of 
the microcapsules was examined using EDXR (AztecEnergy 
EDS Analysis Software, Oxford Instruments, Oxfordshire, 
UK). Electron micrographs of G and G-DCA-SA microcap-
sules were obtained using SEM, and their chemical char-
acterization was obtained using EDXR. The samples were 
mounted on a glass stub with double-sided adhesive tape 
and coated under vacuum with platinum (5 nm) in an argon 
atmosphere prior to examination. Micrographs with different 
magnifications were recorded to study the morphological 
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and surface characteristics of the microcapsules. Multiple 
images at various scales and angles were taken, and those 
that best captured the details of the surface morphological 
changes were used.
Determination of dispersing  
media viscosity
Fifteen milliliter aliquots (n=3) of both preparations  (G-SA 
and G-DCA-SA) were taken from freshly prepared solutions, 
and the viscosity was measured at room temperature using a 
Visco 88 viscometer (Malvern Instruments Limited, Malvern, 
UK). The temperature remained constant at 23°C throughout 
the experiment (monitored by the Visco 88).
Differential scanning calorimetry  
(Dsc) analysis
DSC thermograms of G, DCA, and LVSA powders, their 
physical mixture, and their microencapsulated formulations 
were carried out on a DSC instrument (DSC 8000; Perkin-
Elmer Inc., Waltham, MA, USA). Five  milligram samples 
were placed in sealed aluminum pans and heated at 20°C/
min under a nitrogen atmosphere (flow rate 30 mL/min) in 
the 35°C–240°C range. An empty aluminum pan was used 
as a reference. The equipment was calibrated for baseline 
and temperature with zinc metal.
Fourier transform infrared  
spectroscopy (FTir) studies
FTIR spectra of the pure components, their physical mixture, 
and the microcapsules were recorded via an attenuated total 
reflectance FTIR spectrometer (Spectrum Two™; PerkinElmer), 
and infrared measurements were performed in transmission in 
the scanning range of 450–4,000 cm−1 at room temperature. The 
same G to SA and G to DCA to SA ratios as those analytically 
determined in the microcapsules were used for preparing the 
different physical mixtures that served as controls.
Results and discussion
Morphology, size analysis, and chemical  
characterization of microcapsules
Microcapsules were obtained using LVSA polymer, G, and 
DCA at a constant ratio of 30:1:3,  respectively. Using our 
microencapsulation system, we were able to form microcap-
sules of a similar size. The mean diameters ranged from 1,000 
to 1,150 µm for all batches of both  formulations. The mean 
particle size was not significantly affected by the presence of 
DCA (Figure 1). Microencapsulation efficiency remained simi-
lar, at 93%±5% for G-SA and 90%±7% for G-DCA-SA.
seM
SEM studies of a G-SA microcapsule (Figure 2) and 
G-DCA-SA microcapsules (Figure 3) represent randomly 
selected microcapsules from a few freshly made batches. 
SEM results show microcapsules of consistent uniformity 
and well-defined spherical shapes. G-SA microcapsules 
(Figure 2) appeared slightly larger in size than the 
G-DCA-SA microcapsules (Figure 3). The microcapsule size 
difference between different formulations was not  statistically 
significant. Due to the high-resolution images, we were able 
to conclude that the surfaces of the microcapsules were rough 
but consistent from one microcapsule to another in the sample 









Figure 1 g-sa microcapsules (A) and g-Dca-sa microcapsules (B).
Abbreviations: g-Dca-sa, gliclazide-deoxycholic acid-sodium alginate; g-sa, gliclazide-sodium alginate.





These high-resolution images also revealed ridges on the 
surface of the microcapsules with small crystal depositions. 
The small crystals distributed throughout the microcapsule 
surfaces were believed to be sodium chloride (NaCl), which 
was confirmed by EDXR spectroscopy studies, as discussed 
below  (Figures 4 and 5).
eDXr spectroscopy
In order to further analyze the composition of the micro-
capsule surface for the G-DCA-SA formulation, EDXR 
was used to identify the various surface crystal depositions 
and microcapsule composition including, various ions 
present on the surface of the microcapsules. Analysis of 
200 µm
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WD =20.0 mm
EHT =3.00 kv Signal A=SE2 Aperture size =30.00 µm
WD =10.0 mm
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Figure 2 scanning electron micrographs of gliclazide-sodium alginate microcapsules.
Notes: 200 µm scale (A). surface morphology at 1 µm scale (B) and 10 µm scale (C and D).
200 µm EHT =5.00 kv Signal A=SE2 Aperture size =30.00 µm
WD =5.0 mm
1 µm EHT =5.00 kv Signal A=SE2 Aperture size =30.00 µm
WD =5.0 mm
20 µm EHT =5.00 kv Signal A=SE2 Aperture size =30.00 µm
WD =5.0 mm




Figure 3 scanning electron micrographs of gliclazide-deoxycholic acid-sodium alginate microcapsules at various angles.
Notes: 200 µm scale (A). surface morphology at 1 µm scale (B), 10 µm scale (C), and 20 µm scale (D).
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crystal depositions on the microcapsule  surfaces  (Figure 5) 
revealed high levels of Na and Cl ions, confirming that 
there were small crystals of NaCl on the surface of 
G-DCA-SA microcapsules; this was expected, given 
sodium chloride is a by-product of the ionic-gelation 
methodology of microcapsule production.16,19,20 Both 
formulations showed high levels of sulfur, oxygen, and 
carbon, confirming the  presence of G within the polymer 
matrix for the  formulation, although carbon and oxygen 
are also common to DCA and SA. As for the microcapsule 
surface  composition, EDXR revealed high levels of cal-
cium, carbon, and oxygen, which were expected, given the 
microcapsule wall structure and DCA-reinforced calcium 
alginate matrix system.
Figure 4 energy-dispersive X-ray spectra of the gliclazide-sodium alginate microcapsules.
Notes: Drug composition (A) and surface composition (B), with corresponding analysis (C and D). 1 in (A), and 2 in (B) represent the sites where eDXr spectroscopy 
analyses were undertaken.
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Figure 5 energy-dispersive X-ray spectra of the gliclazide-deoxycholic acid-sodium alginate microcapsules.
Notes: Drug composition (A) and surface composition (B), with corresponding analysis (C and D). 1 in (A), and 2 in (B) represent the sites where eDXr spectroscopy 
analyses were undertaken.
Abbreviation: eDXr, energy dispersive X-ray.





The EDXR assessment of G-SA microcapsules is shown 
in Figure 4, which reveals the surface where analyses were 
done. Figure 4A shows the core of the G-SA microcapsule 
with the corresponding EDXR spectrum (Figure 4C). The 
spectrum shows a high concentration of the sulfur (S) atom, 
unique to the drug G, as no other excipient in the formulation 
contained S atoms. The spectrum also reveals high concen-
trations of calcium (Ca) and oxygen (O), which are likely to 
correspond to the surrounding calcium alginate membrane. 
Figure 4B, on the other hand, is an analysis of the surface, 
with the corresponding EDXR spectrum shown in Figure 4D. 
Figure 4D shows predominant Ca and O activity correspond-
ing to the general surface composition, with some S detected, 
likely due to the deposition of small drug crystals nearby 
or to the penetration of electron rays in the membrane deep 
enough to detect the encapsulated drug.
An example of an EDXR assessment of G-DCA-SA 
microcapsules is shown in Figure 5A, with the respective 
spectrum of the microcapsule surface. In Figure 5C, the 
microcapsule surfaces were not perfectly homogenous, thus 
varying crystal depositions could occur at selected sites 
across the microcapsule surface. Figure 5A exemplifies the 
core of the G-DCA-SA microcapsules, and Figure 5C shows 
a high concentration of S atoms, which is expected from G 
molecules. Figure 5B illustrates the surface surrounding 
the drug in the G-DCA-SA microcapsules, and Figure 5D 
shows a high concentration of Cl and Ca atoms, which are 
expected to adhere to the surface of the microcapsules. These 
atoms derive from the used vehicle carrying the formed 
microcapsules (CaCl
2
). Furthermore, Figure 5C and D 
show the  chemical characteristics of the microcapsules, 
with dominant ions (Na, O, Ca, and Cl) that are expected 
for typical G-DCA-SA microcapsules prepared via ionic-
gelation methodology.
Viscosity of the microencapsulated  
formulation
Table 1 shows the viscosity, shear rate, shear stress, and torque 
force for all microencapsulated formulations under various 
speeds (20, 35, 61, 107, 187, 327, 572, and 1,000 rpm). The 
G-SA formulation was more viscous, but both formulations 
behaved as almost non-Newtonian fluids under shear stress. 
Thus, and as anticipated from our previous studies, both 
formulations behave as thixotropic non-Newtonian fluids 
under increasing stress, as evidenced by parallel reduc-
tions in their apparent viscosity.16,17 Further evidence of the 
thixotropic-pseudoplastic behavior of both formulations can 
be seen in the proportional increases in torque and shear rate 
following rising shear stress forces and associated decrease 
in the viscosity, characteristic of non-Newtonian fluid, and 
thixotropic behavior of the polymer.21–27 The application of 
the stirring rod in the solutions at increasing speeds resulted 
in the solutions forming rapid circular motions away from the 
site of centripetal force origin, suggesting that both formula-
tions also behaved in a non-Weissenberg fashion.27,28
Thermal analysis of the microcapsules
DSC is an important technology for the thermal character-
ization of various materials. DSC establishes a connection 
between temperature and specific physical properties of 
 substances, such as crystallization and melting tem-
perature. It is commonly used to determine the enthalpy 
Table 1 Viscosities and related parameters of both microencapsulated formulations: g-sa and g-Dca-sa (n=3)










g-sa 1 20 UD UD UD UD
2 35 UD UD UD UD
3 61 UD UD UD UD
4 107 37±0.35 124.9±0.1 0.17±0.01 4.6±0.04
5 187 34±0.34 221.8±0.25 0.28±0.03 7.7±0.01
6 327 30±0.3 385.1±0.4 0.43±0.05 11.6±0.04
7 572 26±0.26 680.5±0.7 0.64±0.04 17.3±0.02
8 1,000 21±0.2 1,194±1 0.93±0.06 25.4±0.06
g-Dca-sa 1 20 UD UD UD UD
2 35 UD UD UD UD
3 61 UD UD UD UD
4 107 UD UD UD UD
5 187 24±0.24 221.9±0.3 0.19±0.02 5.1±0.05
6 327 23±0.22 385.3±0.5 0.34±0.04 9.1±0.03
7 572 21±0.21 680.8±0.7 0.60±0.04 16.2±0.06
8 1,000 20±0.2 1,195±2 0.97±0.1 26.4±0.03
Abbreviations: g-Dca-sa, gliclazide-deoxycholic acid-sodium alginate; g-sa, gliclazide-sodium alginate; UD, undetected (below the instrument limit of detection).
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associated with the process of microencapsulation.29 In 
 microencapsulation, DSC measures how physical properties 
of G and DCA molecules change, along with temperature 
against time.30,31 This occurs through determining the 
temperature and heat flow (35°C–240°C) associated with 
G transitions as a function of time. DSC spectra were ana-
lyzed for G powder (Figure 6A), DCA powder (Figure 6B), 
SA powder ( Figure 6C), G-DCA-SA powder (Figure 6D), 
G-SA microcapsules ( Figure 6E), and G-DCA-SA 
microcapsules (Figure 6F).
DSC analysis of DCA powder (Figure 6B) showed a 
small peak at 178°C, indicative of a DCA melting point. 
A similar peak at 179°C was clearly observed with G analysis 
(Figure 6A), which is indicative of its melting point. The 
DSC analysis of DCA and G microcapsules (Figure 6F) 
showed transparent and interference-free integration of two 
predominant peaks - one corresponding to G, and the other 
a slight shift to the right when compared to individual DCA 
and SA powders, which could represent possible chemical 
interactions between SA and DCA in the microcapsule 
matrix, alterations in the crystallinity of DCA and SA within 
the temperature range used for analysis, or polymorphism 
leading to an endothermic shift to the right.32,33
As for the G-SA microcapsule (Figure 6E) analysis, 
there was a very similar graph with two prominent peaks – 
one representing G (160°C), and the other the SA powder 
(193°C), and could represent plasticization of the polymer.34 
SA powder (Figure 6C) showed a significant peak at 200°C, 
indicative of the endothermic thermal behavior of the 
polymer and in line with the SA peak observed at 200°C 
in G-DCA-SA microcapsules (Figure 6F).35 G was not 
chemically modified or did not participate in any significant 
reaction, as evidenced by endothermic peaks characteristic 
of the drug following analysis of the microcapsules.36,37 This 
was confirmed by the combined powders of G, DCA, and SA 
(Figure 6D), which showed two peaks representing the G and 
SA peaks, which was a slight shift from the original G peak, 
thus suggesting that there were no significant chemical inter-
actions occurring between DCA, G, and SA in the powder 
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Figure 6 Differential scanning calorimetry thermograms of g powder (A), Dca powder (B), sa powder (C), g-Dca-sa powder (D), g-sa microcapsules (E), and g-Dca-
sa microcapsules (F).
Abbreviations: Dca, deoxycholic acid; g-Dca-sa, gliclazide-deoxycholic acid-sodium alginate; g-sa, gliclazide-sodium alginate; sa, sodium alginate; g, gliclazide.





peaks overlapping. Overall, this indicates good stability of G 
and DCA in the formulated microcapsules. Interestingly, the 
DCA peak (Figure 6B) noted in the DCA individual powder 
did not appear in the G-DCA-SA powder mixture of the 
combined powders (Figure 6D). This may be due to a shift 
in the thermal capacity within the 35°C–240°C range, or to 
interactions or potential crystallinity.30,37 The DCA peak was 
also absent in the G-DCA-SA microcapsules, possibly due to 
DCA formulated in the combined G-DCA-SA microcapsules 
existing in an amorphous or disordered crystalline phase as 
well as a solid state solution (Figure 6F).37
The shift in the thermal profile of G in the microencap-
sulation form (Figure 6E) suggests that the drug  solubilizes 
in the polymer matrix via ionic interactions, while no 
significant chemical reaction takes place between G or any 
of the formulation excipients, as shown by FTIR studies 
(Figure 7) and previous in vivo and ex vivo work in our 
laboratory.14,34,38–40 Comparing all peaks, G does not appar-
ently participate in significant crosslinking reactions, and 
retains its chemical integrity during the microencapsulation 
process, as evidenced by FTIR studies.
FTir spectral studies
The FTIR spectra were used to confirm the chemical com-
patibility of G with the SA polymer and DCA in the micro-
encapsulation formulation. FTIR spectra were analyzed 
for G powder (Figure 7A), DCA powder (Figure 7B), SA 
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Figure 7 Fourier transform infrared spectra of g powder (A), Dca powder (B), sa powder (C), g-Dca-sa powder (D), g-sa microcapsules (E), and g-Dca-sa 
microcapsules (F).
Abbreviations: Dca, deoxycholic acid; g-Dca-sa, gliclazide-deoxycholic acid-sodium alginate; g-sa, gliclazide-sodium alginate; sa, sodium alginate; g, gliclazide; T, transmittance.
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microcapsules (Figure 7E), and G-DCA-SA microcapsules 
(Figure 7F).
The spectrum of G-SA for the C=O band in carbonyl 
group shows a sharp peak at 1,707 cm−1 (Figure 7A), which 
was consistent across both microencapsulated formula-
tions (Figure 7E and F) and powder mixture (Figure 7D). 
Again, for the S=O band in sulfonamide, the G-SA spectra 
show peaks at 1,161 cm−1, and for the amino group, peaks 
of 3,260 cm−1 in the microcapsules and powder mixture. 
For DCA powder (Figure 7B), the spectrum is in line with 
previously published work.41 In G-DCA-SA microcapsules 
(Figure 7F) and G-DCA-SA powder (Figure 7D), there 
was a small shift of the G peak to the right (1,603 cm−1). 
This may be due to the dilution of DCA concentration 
in the mixture, or may occur during the microencapsula-
tion process. The more likely reason is the dilution of the 
powder in the G-DCA-SA mixture, which is in line with 
the thermal  analysis above (Figure 6D). In addition, the 
FTIR spectrum of SA powder (Figure 7C) is consistent 
with the literature;42 however, the spectra of G-DCA-SA 
microcapsules and G-DCA-SA powder mixture seem to be 
weaker and seem to display less bond-peak activity.43 This 
may be due to the dilution of the sample, which is consis-
tent with the thermal analysis of the G-DCA-SA powder 
mixture (Figure 7D). Overall, FTIR spectra of G suggest 
that microencapsulation of G with SA and DCA does not 
significantly compromise the chemical composition and 
structural integrity of the G molecules, as no significant 
chemical reaction occurred between the drug and any of 
the formulation excipients.
Conclusion
Microencapsulation of G and DCA is a novel and viable 
technique that is useful for targeted drug delivery. The new 
formulation designed in this study displays appropriate 
excipient compatibility and structural morphology with 
thixotropic-pseudoplastic behavior. This microencapsulated 
formulation is expected to ensure adequate encapsulation of 
labile compounds, such as primary BAs, which seem benefi-
cial in conjunction with G, in diabetes treatment. Along with 
the use of microencapsulation, DCA will play a crucial role 
in optimizing G absorption in the ileum, which will help to 
further increase its antidiabetic effect. However, more work 
is needed to better evaluate the drug release profile from the 
microcapsules. The authors’ future study aims at investigat-
ing the release kinetics of the formulation in various pH and 
temperature values and establishing its targeted delivery 
characteristics, which is anticipated to have significant impact 
on future in vivo studies.
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